Sanofi Logo
CAD Logo

HOW ENJAYMO WORKS

ENJAYMO is a chemotherapy-free treatment option that helps stop hemolysis in its tracks
To understand the way ENJAYMO works, it's important to know:
What Happens in People Living with CAD
Hemolysis & The Complement Pathway
How ENJAYMO Can Help
What Happens in people living with CAD
When you have Cold Agglutinin Disease (CAD), your immune system makes cold agglutinin antibodies that mistake red blood cells as a threat to the body.
When the antibodies come close to a red blood cell, they attach. This signals a specific pathway in the immune system called the classical complement pathway to activate and destroy the red blood cells (hemolysis).
If your body destroys red blood cells faster than it can replace them, you may develop anemia. When you have CAD, hemolysis can be hard to predict and if ongoing, can lead to chronic anemia. Learn more about CAD.
HOW ENJAYMO WORKS
In CAD, only the activation of the classical complement pathway leads to hemolysis—the destruction of red blood cells. ENJAYMO is designed to help stop hemolysis before it starts.
By binding to C1s, a component of the first protein in the classical complement pathway, ENJAYMO helps stop the chain reaction at the very beginning, preventing your red blood cells from being destroyed. While it inhibits C1s, ENJAYMO leaves the other complement pathways (lectin and alternative pathways) alone to carry out their normal immune functions.
Taking enjaymo
See how ENJAYMO should be taken and what you can expect during treatment.
INDICATION
ENJAYMO® is a prescription medicine used to treat the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD).

It is not known if ENJAYMO is safe and effective in children.
INDICATION & IMPORTANT SAFETY INFORMATION
IMPORTANT SAFETY INFORMATION
Do not receive ENJAYMO if you are allergic to sutimlimab-jome or any of the ingredients in ENJAYMO.
ENJAYMO can cause serious side effects, including:
Serious Infections: ENJAYMO is a prescription medicine that affects your immune system. ENJAYMO can lower the ability of your immune system to fight infections. People who take ENJAYMO may have an increased risk of getting infections caused by certain kinds of bacteria such as Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae. These infections may be serious or life-threatening. Some infections may quickly become life-threatening or cause death if not recognized and treated early.
You need to receive vaccinations against infections caused by certain kinds of bacteria at least 2 weeks before your first dose of ENJAYMO. You may need to have additional vaccinations during treatment.
If your healthcare provider decides that urgent treatment with ENJAYMO is needed, you should receive vaccinations as soon as possible.
Vaccinations may reduce the risk of these infections, but do not prevent all infections. Call your healthcare provider or get medical help right away if you get any new signs and symptoms of an infection, including:
fever
severe headache with stiff neck or back
pain during urination or urinating more
often than usual
cough or difficulty breathing
flu-like symptoms
pain, redness, or swelling of the skin
Infusion-related reactions: Treatment with ENJAYMO may cause infusion-related reactions, including allergic reactions that may be serious or life-threatening. Your healthcare provider may slow down or stop your ENJAYMO infusion if you have an infusion-related reaction and will treat your symptoms if needed. Tell your healthcare provider right away if you develop symptoms during your ENJAYMO infusion that may mean you are having an infusion-related reaction, including:
shortness of breath
decrease in blood pressure
chest discomfort
rapid heartbeat
nausea
injection site reaction
flushing
headache
dizziness
rash
itchy skin
Risk of autoimmune disease: ENJAYMO may increase your risk for developing an autoimmune disease such as systemic lupus erythematosus (SLE). Tell your healthcare provider and get medical help if you develop any symptoms of SLE, including:
joint pain or swelling
rash on the cheeks and nose
unexplained fever
If you have CAD and you stop receiving ENJAYMO, your healthcare provider should monitor you closely for the return of your symptoms after you stop ENJAYMO. Stopping ENJAYMO may cause the breakdown of your red blood cells due to CAD return. Symptoms or problems that can happen due to red blood cell breakdown include:
tiredness
shortness of breath
rapid heart rate
blood in your urine or
dark urine
The most common side effects of ENJAYMO include:
increase in blood
pressure
urinary tract infection
respiratory tract
infection
bacterial infection
swelling in lower legs
or hands
joint pain
headache
nausea
runny nose
bluish color to
the lips and skin
dizziness
feeling tired or weak
cough
changes in color or
sensation in the fingers
and toes (Raynaud's
phenomenon)
These are not all the possible side effects of ENJAYMO. Call your doctor for medical advice about side effects.
Before receiving ENJAYMO, tell your healthcare provider about all of your medical conditions, including if you:
have a fever or infection, including a history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
have an autoimmune disease such as systemic lupus erythematosus (SLE), also known as lupus.
are pregnant or plan to become pregnant. It is not known if ENJAYMO will harm your unborn baby.
are breastfeeding or plan to breastfeed. It is not known if ENJAYMO passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
Back to the top